Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2008

01-12-2008

The role of DNA synthesis imaging in cancer in the era of targeted therapeutics

Authors: Sridhar Nimmagadda, Anthony F. Shields

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Login to get access

Abstract

Non-specific targets such as DNA and microtubules have been the mainstay of cancer therapeutics and the most effective clinical agents until a decade ago. Advances in genetics, molecular and cellular biology over the past decade led to the development of a new generation of agents that are far more specific and effective. In contrast to progress seen with therapeutic agents, general monitoring targets such as proliferation imaging are just gaining momentum and targeted imaging is still in its infancy. In these paradoxical times, this review assesses the role of proliferation imaging in monitoring the efficacy of targeted therapeutics.
Literature
1.
Laverman, P., Boerman, O. C., Corstens, F. H., & Oyen, W. J. (2002). Fluorinated amino acids for tumour imaging with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 29, 681–690.PubMed
2.
Yoshimoto, M., Waki, A., Obata, A., Furukawa, T., Yonekura, Y., & Fujibayashi, Y. (2004). Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nuclear Medicine and Biology, 31, 859–865.PubMed
3.
Mankoff, D. A., Shields, A. F., & Krohn, K. A. (2005). PET imaging of cellular proliferation. Radiologic Clinics of North America, 43, 153–167.PubMed
4.
Kenny, L. M., Aboagye, E. O., & Price, P. M. (2004). Positron emission tomography imaging of cell proliferation in oncology. Clinical Oncology (Royal College of Radiologists (Great Britain)), 16, 176–185.
5.
Christman, D., Crawford, E. J., Friedkin, M., & Wolf, A. P. (1972). Detection of DNA synthesis in intact organisms with positron-emitting (11C-methyl)thymidine. Proceedings of the National Academy of Sciences of the United States of America, 69, 988–992.PubMed
6.
Shields, A. F., Coonrod, D. V., Quackenbush, R. C., & Crowley, J. J. (1987). Cellular sources of thymidine nucleotides: Studies for PET. Journal of Nuclear Medicine, 28, 1435–1440.PubMed
7.
Quackenbush, R. C., & Shields, A. F. (1988). Local Re-utilization of thymidine in normal mouse tissues as measured with iododeoxyuridine. Cell and Tissue Kinetics, 21, 381–387.PubMed
8.
Shields, A. F., Lim, K., Grierson, J., Link, J., & Krohn, K. A. (1990). Utilization of labeled thymidine in DNA synthesis: studies for PET. Journal of Nuclear Medicine, 31, 337–342.PubMed
9.
Adler, R., & McAuslan, B. R. (1974). Expression of thymidine kinase variants is a function of the replicative state of cells. Cell, 2, 113–117.PubMed
10.
Bello, L. J. (1974). Regulation of thymidine kinase synthesis in human cells. Experimental Cell Research, 89, 263–274.PubMed
11.
Johnson, L. F., Rao, L. G., & Muench, A. J. (1982). Regulation of thymidine kinase enzyme level in serum-stimulated mouse 3T6 fibroblasts. Experimental Cell Research, 138, 79–85.PubMed
12.
Sherley, J. L., & Kelly, T. J. (1988). Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. Journal of Biological Chemistry, 263, 375–382.PubMed
13.
Broet, P., Romain, S., Daver, A., Ricolleau, G., Quillien, V., Rallet, A., et al. (2001). Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients. Journal of Clinical Oncology, 19, 2778–2787.PubMed
14.
Hallek, M., Wanders, L., Strohmeyer, S., & Emmerich, B. (1992). Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin’s lymphoma and a broad range of potential clinical applications. Annals of Hematology, 65, 1–5.PubMed
15.
Svobodova, S., Topolcan, O., Holubec, L., Treska, V., Sutnar, A., Rupert, K., et al. (2007). Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Research, 27, 1907–1909.PubMed
16.
Romain, S., Christensen, I. J., Chinot, O., Balslev, I., Rose, C., Martin, P. -M., et al. (1995). Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. International Journal of Cancer, 61, 7–12.
17.
Dou, Q. P., Zhao, S., Levin, A. H., Wang, J., Helin, K., & Pardee, A. B. (1994). G1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. Journal of Biological Chemistry, 269, 1306–1313.PubMed
18.
Shields, A., Grierson, J., Dohmen, B., Machulla, H. -J., Stayanoff, J., Lawhorn-Crews, J., et al. (1998). Imaging proliferation in vivo with [18F-]FLT and positron emission tomography. Nature Medicine, 4, 1334–1336.PubMed
19.
Carreras, C. W., & Santi, D. V. (1995). The catalytic mechanism and structure of thymidylate synthase. Annual Reviews of Biochemical, 64, 721–762.
20.
Peters, G. J., Backus, H. H., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C. L., et al. (2002). Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica et Biophysica Acta, 1587, 194–205.PubMed
21.
van Triest, B., Pinedo, H. M., van Hensbergen, Y., Smid, K., Telleman, F., Schoenmakers, P. S., et al. (1999). Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clinical Cancer Research, 5, 643–654.PubMed
22.
Pestalozzi, B. C., Peterson, H. F., Gelber, R. D., Goldhirsch, A., Gusterson, B. A., Trihia, H., et al. (1997). Prognostic importance of thymidylate synthase expression in early breast cancer. Journal of Clinical Oncology, 15, 1923–1931.PubMed
23.
Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., et al. (1995). Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Research, 55, 1407–1412.PubMed
24.
Friedkin, M., & Roberts, D. (1954). The enzymatic synthesis of nucleosides. II. Thymidine and related pyrimidine nucleosides. Journal of Biological Chemistry, 207, 257–266.PubMed
25.
Friedkin, M., & Roberts, D. (1954). The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. Journal of Biological Chemistry, 207, 245–256.PubMed
26.
Iltzsch, M. H., el Kouni, M. H., & Cha, S. (1985). Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry, 24, 6799–6807.PubMed
27.
Sumizawa, T., Furukawa, T., Haraguchi, M., Yoshimura, A., Takeyasu, A., Ishizawa, M., et al. (1993). Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. Journal of Biochemistry (Tokyo), 114, 9–14.
28.
Usuki, K., Saras, J., Waltenberger, J., Miyazono, K., Pierce, G., Thomason, A., et al. (1992). Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochemical and Biophysical Research Communications, 184, 1311–1316.PubMed
29.
Toi, M., Rahman, M. A., Bando, H., & Chow, L. W. C. (2005). Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. The Lancet Oncology, 6, 158–166.PubMed
30.
Klecker Jr., R. W., & Collins, J. M. (2001). Thymidine phosphorylase as a target for imaging and therapy with thymine analogs. Cancer Chemotherapy and Pharmacology, 48, 407–412.PubMed
31.
Dimitrakopoulou, A., Strauss, L. G., Clorius, J. H., Ostertag, H., Schlag, P., Heim, M., et al. (1993). Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. Journal of Nuclear Medicine, 34, 1075–1081.PubMed
32.
Dimitrakopoulou-Strauss, A., Strauss, L. G., Schlag, P., Hohenberger, P., Mohler, M., Oberdorfer, F., et al. (1998). Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. Journal of Nuclear Medicine, 39, 1197–1202.PubMed
33.
Shields, A. F., Graham, M. M., Kozawa, S. M., Kozell, L. B., Link, J. M., Swenson, E. R., et al. (1992). Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. Journal of Nuclear Medicine, 33, 581–584.PubMed
34.
Mankoff, D. A., Shields, A. F., Graham, M. M., Link, J. M., & Krohn, K. A. (1996). A graphical analysis method for estimating blood-to-tissue transfer constants for tracers with labeled metabolites. Journal of Nuclear Medicine, 37, 2049–2057.PubMed
35.
Shields, A. F., Mankoff, D., Graham, M. M., Zheng, M., Kozawa, S. M., Link, J., et al. (1996b). Analysis of [2-11C]thymidine blood metabolites for imaging with PET. Journal of Nuclear Medicine, 37, 290–296.PubMed
36.
Mankoff, D. A., Shields, A. F., Graham, M. M., Link, J. M., Eary, J. F., & Krohn, K. A. (1998). Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis. Journal of Nuclear Medicine, 39, 1043–1055.PubMed
37.
Russo, A., Gianni, L., Kinsella, T. J., Klecker Jr., R. W., Jenkins, J., Rowland, J., et al. (1984). Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. Cancer Research, 44, 1702–1705.PubMed
38.
Bergstrom, M., Lu, L., Fasth, K. J., Wu, F., Bergstrom-Pettermann, E., Tolmachev, V., et al. (1998). In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. Journal of Nuclear Medicine, 39, 1273–1279.PubMed
39.
Gudjonssona, O., Bergstrom, M., Kristjansson, S., Wu, F., Nyberg, G., Fasth, K. J., et al. (2001). Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. Nuclear Medicine and Biology, 28, 59–65.PubMed
40.
Tjuvajev, J., Muraki, A., Ginos, J., Berk, J., Koutcher, J., Ballon, D., et al. (1993). Iododeoxyuridine uptake and retention as a measure of tumor growth. Journal of Nuclear Medicine, 34, 1152–1162.PubMed
41.
Tjuvajev, J. G., Macapinilac, H. A., Daghighian, F., Scott, A. M., Ginos, J. Z., Finn, R. D., et al. (1994). Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. Journal of Nuclear Medicine, 35, 1407–1417.PubMed
42.
Blasberg, R. G., Roelcke, U., Weinreich, R., Beattie, B., von Ammon, K., Yonekawa, Y., et al. (2000). Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Research, 60, 624–635.PubMed
43.
Rasey, J. S., Grierson, J. R., Wiens, L. W., Kolb, P. D., & Schwartz, J. L. (2002). Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. Journal of Nuclear Medicine, 43, 1210–1217.PubMed
44.
Toyohara, J., Waki, A., Takamatsu, S., Yonekura, Y., Magata, Y., & Fujibayashi, Y. (2002). Basis of FLT as a cell proliferation marker: Comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nuclear Medicine and Biology, 29, 281–287.PubMed
45.
Schwartz, J. L., Tamura, Y., Jordan, R., Grierson, J. R., & Krohn, K. A. (2004). Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy-3′fluorothymidine uptake. Nuclear Medicine and Biology, 31, 419–423.PubMed
46.
Leyton, J., Latigo, J. R., Perumal, M., Dhaliwal, H., He, Q., & Aboagye, E. O. (2005). Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F-]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Research, 65, 4202–4210.PubMed
47.
Oyama, N., Ponde, D. E., Dence, C., Kim, J., Tai, Y. C., & Welch, M. J. (2004). Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. Journal of Nuclear Medicine, 45, 519–525.PubMed
48.
Sherr, C. J., & Roberts, J. M. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Development, 9, 1149–1163.
49.
Rotheneder, H., Geymayer, S., & Haidweger, E. (1999). Transcription factors of the Sp1 family: Interaction with E2F and regulation of the murine thymidine kinase promoter. Journal of Molecular Biology, 293, 1005–1015.PubMed
50.
Sugiyama, M., Sakahara, H., Sato, K., Harada, N., Fukumoto, D., Kakiuchi, T., et al. (2004). Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. Journal of Nuclear Medicine, 45, 1754–1758.PubMed
51.
Apisarnthanarax, S., Alauddin, M. M., Mourtada, F., Ariga, H., Raju, U., Mawlawi, O., et al. (2006). Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clinical Cancer Research, 12, 4590–4597.PubMed
52.
Yang, Y. J., Ryu, J. S., Kim, S. Y., Oh, S. J., Im, K. C., Lee, H., et al. (2006). Use of 3′-deoxy-3′-[18F-]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. European Journal of Nuclear Medicine and Molecular Imaging, 33, 412–419.PubMed
53.
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006). Anticancer activities of histone deacetylase inhibitors. Nature Reviews. Drug Discovery, 5, 769–784.PubMed
54.
Catley, L., Weisberg, E., Tai, Y. T., Atadja, P., Remiszewski, S., Hideshima, T., et al. (2003). NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102, 2615–2622.PubMed
55.
Leyton, J., Alao, J. P., Da Costa, M., Stavropoulou, A. V., Latigo, J. R., Perumal, M., et al. (2006). In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F-]fluorothymidine positron emission tomography. Cancer Research, 66, 7621–7629.PubMed
56.
Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO Journal, 19, 3159–3167.PubMed
57.
Janne, P. A., von Pawel, J., Cohen, R. B., Crino, L., Butts, C. A., Olson, S. S., et al. (2007). Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. Journal of Clinical Oncology, 25, 3936–3944.PubMed
58.
Zinner, R. G., Nemunaitis, J., Eiseman, I., Shin, H. J., Olson, S. C., Christensen, J., et al. (2007). Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clinical Cancer Research, 13, 3006–3014.PubMed
59.
Dorow, D. S., Cullinane, C., Conus, N., Roselt, P., Binns, D., McCarthy, T. J., et al. (2006). Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. European Journal of Nuclear Medicine and Molecular Imaging, 33, 441–452.PubMed
60.
Carvajal, R. D., Tse, A., & Schwartz, G. K. (2006). Aurora kinases: New targets for cancer therapy. Clinical Cancer Research, 12, 6869–6875.PubMed
61.
Chan, F., Sun, C., Perumal, M., Nguyen, Q. D., Bavetsias, V., McDonald, E., et al. (2007). Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular Cancer Therapeutics, 6, 3147–3157.PubMed
62.
Barthel, H., Cleij, M. C., Collingridge, D. R., Hutchinson, O. C., Osman, S., He, Q., et al. (2003). 3′-Deoxy-3′-[18F-]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Research, 63, 3791–3798.PubMed
63.
Shields, A., Grierson, J. R., Muzik, O., Stayanoff, J. C., Lawhorn-Crews, J., Obradovich, J. E., et al. (2002). Kinetics of 3′-deoxy-3′-[18F-]fluorothymidine uptake and retention in dogs. Molecular Imaging Biology, 4(1), 83–89.
64.
Muzi, M., Mankoff, D. A., Grierson, J. R., Wells, J. M., Vesselle, H., & Krohn, K. A. (2005). Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. Journal of Nuclear Medicine, 46, 371–380.PubMed
65.
Shields, A., Briston, D., Chandupatla, S., Douglas, K., Lawhorn-Crews, J., Collins, J., et al. (2005). A simplified analysis of 18F- 3’-fluorothymidine metabolism and retention. European Journal of Nuclear Medicine and Molecular Imaging, 32, 1269–1275.PubMed
66.
Munch-Petersen, B., Cloos, L., Tyrsted, G., & Eriksson, S. (1991). Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. Journal of Biological Chemistry, 266, 9032–9038.PubMed
67.
Been, L. B., Elsinga, P. H., de Vries, J., Cobben, D. C., Jager, P. L., Hoekstra, H. J., et al. (2006). Positron emission tomography in patients with breast cancer using 18F-3′-deoxy-3′-fluoro-l-thymidine (18F-FLT): A pilot study. European Journal of Surgical Oncology, 32, 39–43.PubMed
68.
Dittmann, H., Dohmen, B. M., Paulsen, F., Eichhorn, K., Eschmann, S. M., Horger, M., et al. (2003). [18F-]FLT PET for diagnosis and staging of thoracic tumours. European Journal of Nuclear Medicine and Molecular Imaging, 30, 1407–1412.PubMed
69.
Kenny, L. M., Vigushin, D. M., Al-Nahhas, A., Osman, S., Luthra, S. K., Shousha, S., et al. (2005). Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F-]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Research, 65, 10104–10112.PubMed
70.
Buck, A. K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., et al. (2003). Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. Journal of Nuclear Medicine, 44, 1426–1431.PubMed
71.
Vesselle, H., Grierson, J., Muzi, M., Pugsley, J. M., Schmidt, R. A., Rabinowitz, P., et al. (2002). In vivo validation of 3′deoxy-3′-[18F-]fluorothymidine (18F-FLT) as a proliferation imaging tracer in humans: Correlation of 18F-FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clinical Cancer Research, 8, 3315–3323.PubMed
72.
Yamamoto, Y., Nishiyama, Y., Ishikawa, S., Nakano, J., Chang, S. S., Bandoh, S., et al. (2007). Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 34(10), 1610–1616.PubMed
73.
Jeraj, R., McCall, K., Simoncic, U., & Nickles, J. (2007). Monitoring of radiation effects with FLT-PET imaging. In Joint Molecular Imaging Conference, Society of Molecular Imaging and Academy of Molecular Imaging: Providence, RI.
74.
McArthur, G., Hicks, R., Binns, D., Shalinsky, D., McCarthy, T., Anderes, K., et al. (2007). Positron-emission tomography reveals early flare in uptake of FLT in tumors following chemotherapy with gemcitabine. [abstract]. In Joint Molecular Imaging Conference, Society of Molecular Imaging and Academy of Molecular Imaging: Providence, RI.
75.
Troost, E. G., Vogel, W. V., Merkx, M. A., Slootweg, P. J., Marres, H. A., Peeters, W. J., et al. (2007). 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. Journal of Nuclear Medicine, 48, 726–735.PubMed
76.
van Westreenen, H. L., Cobben, D. C., Jager, P. L., van Dullemen, H. M., Wesseling, J., Elsinga, P. H., et al. (2005). Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. Journal of Nuclear Medicine, 46, 400–404.PubMed
77.
Smyczek-Gargya, B., Fersis, N., Dittmann, H., Vogel, U., Reischl, G., Machulla, H. J., et al. (2004). PET with 18F-fluorothymidine for imaging of primary breast cancer: A pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 31, 720–724.PubMed
78.
Kenny, L., Coombes, R. C., Vigushin, D. M., Al-Nahhas, A., Shousha, S., & Aboagye, E. O. (2007). Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[18F-]fluorothymidine positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 34(9), 1339–1347.PubMed
79.
Pio, B. S., Park, C. K., Pietras, R., Hsueh, W. A., Satyamurthy, N., Pegram, M. D., et al. (2006). Usefulness of 3′-[18F-]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Molecular Imaging and Biology, 8, 36–42.PubMed
80.
Buck, A. K., Bommer, M., Stilgenbauer, S., Juweid, M., Glatting, G., Schirrmeister, H., et al. (2006). Molecular imaging of proliferation in malignant lymphoma. Cancer Research, 66, 11055–11061.PubMed
81.
Wagner, M., Seitz, U., Buck, A., Neumaier, B., Schultheiss, S., Bangerter, M., et al. (2003). 3′-[18F-]fluoro-3′-deoxythymidine ([18F-]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Research, 63, 2681–2687.PubMed
82.
Herrmann, K., Wieder, H. A., Buck, A. K., Schoffel, M., Krause, B. J., Fend, F., et al. (2007). Early response assessment using 3′-deoxy-3′-[18F-]fluorothymidine-positron emission tomography in high-grade non-Hodgkin’s lymphoma. Clinical Cancer Research, 13, 3552–3558.PubMed
83.
Kasper, B., Egerer, G., Gronkowski, M., Haufe, S., Lehnert, T., Eisenhut, M., et al. (2007). Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG-and FLT-PET. Leukemia & Lymphoma, 48, 746–753.
84.
Wieder, H., Ott, K., Zimmermann, F., Nekarda, H., Stollfuss, J., Watzlowik, P., et al. (2002). PET imaging with [11C-]methyl-l-methionine for therapy monitoring in patients with rectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 29, 789–796.PubMed
85.
Muzi, M., Spence, A. M., O’Sullivan, F., Mankoff, D. A., Wells, J. M., Grierson, J. R., et al. (2006). Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. Journal of Nuclear Medicine, 47, 1612–1621.PubMed
86.
Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., et al. (2005). Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. Journal of Nuclear Medicine, 46, 945–952.PubMed
87.
Choi, S. J., Kim, J. S., Kim, J. H., Oh, S. J., Lee, J. G., Kim, C. J., et al. (2005). [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 32, 653–659.PubMed
88.
Saga, T., Kawashima, H., Araki, N., Takahashi, J. A., Nakashima, Y., Higashi, T., et al. (2006). Evaluation of primary brain tumors with FLT-PET: Usefulness and limitations. Clinical Nuclear Medicine, 31, 774–780.PubMed
89.
Yamamoto, Y., Wong, T. Z., Turkington, T. G., Hawk, T. C., Reardon, D. A., & Coleman, R. E. (2006). 3′-Deoxy-3′-[18F-]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: Comparison with Gd-DTPA enhanced magnetic resonance imaging. Molecular Imaging and Biology, 8, 340–347.PubMed
90.
Schiepers, C., Chen, W., Dahlbom, M., Cloughesy, T., Hoh, C. K., & Huang, S. C. (2007). 18F-fluorothymidine kinetics of malignant brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 34, 1003–1011.PubMed
91.
Bading, J. R., Shahinian, A. H., Vail, A., Bathija, P., Koszalka, G. W., Koda, R. T., et al. (2004). Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-beta-d-arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nuclear Medicine and Biology, 31, 407–418.PubMed
92.
Ebuchi, M., Sakamoto, S., Kudo, H., Nagase, J., & Endo, M. (1995). Clinicopathological stages and pyrimidine nucleotide synthesis in human mammary carcinomas. Anticancer Research, 15, 1481–1484.PubMed
93.
Sun, H., Mangner, T. J., Collins, J. M., Muzik, O., Douglas, K., & Shields, A. F. (2005). Imaging DNA synthesis in vivo with 18F-FMAU and PET. Journal of Nuclear Medicine, 46, 292–296.PubMed
94.
Sun, H., Sloan, A., Mangner, T. J., Vaishampayan, U., Muzik, O., Collins, J. M., et al. (2005). Imaging DNA synthesis with 18F-FMAU and positron emission tomography in patients with cancer. European Journal of Nuclear Medicine and Molecular Imaging, 32, 15–22.PubMed
95.
Collins, J. M., Klecker, R. W., & Katki, A. G. (1999). Suicide prodrugs activated by thymidylate synthase: Rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues. Clinical Cancer Research, 5, 1976–1981.PubMed
96.
Kao, C. H., Waki, A., Sassaman, M. B., Jagoda, E. M., Szajek, L. P., Ravasi, L., et al. (2002). Evaluation of [76Br]FBAU 3′,5′-dibenzoate as a lipophilic prodrug for brain imaging. Nuclear Medicine and Biology, 29, 527–535.PubMed
97.
Lu, L., Bergstrom, M., Fasth, K. J., & Langstrom, B. (2000). Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. Journal of Nuclear Medicine, 41, 1746–1752.PubMed
98.
Borbath, I., Gregoire, V., Bergstrom, M., Laryea, D., Langstrom, B., & Pauwels, S. (2002). Use of 5-[(76)Br]bromo-2′-fluoro-2′-deoxyuridine as a ligand for tumour proliferation: Validation in an animal tumour model. European Journal of Nuclear Medicine and Molecular Imaging, 29, 19–27.PubMed
99.
Xing, T., Wu, F., Brodin, O., Fasth, K. J., Langstrom, B., & Bergstrom, M. (2000). In vitro PET evaluations in lung cancer cell lines. Anticancer Research, 20, 1375–1380.PubMed
100.
Lu, L., Samuelsson, L., Bergstrom, M., Sato, K., Fasth, K. J., & Langstrom, B. (2002). Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. Journal of Nuclear Medicine, 43, 1688–1698.PubMed
101.
Nimmagadda, S., Mangner, T. J., Sun, H., Klecker Jr., R. W., Muzik, O., Lawhorn-Crews, J. M., et al. (2005). Biodistribution and radiation dosimetry estimates of 1-(2′-deoxy-2′-18F-Fluoro-1-beta-d-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. Journal of Nuclear Medicine, 46, 1916–1922.PubMed
102.
Tehrani, O. S., Douglas, K. A., Lawhorn-Crews, J. M., & Shields, A. F. (2008). Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. European Journal of Nuclear Medicine and Molecular Imaging, In press (Feb 12).
103.
Jackman, A. L., Taylor, G. A., Calvert, A. H., & Harrap, K. R. (1984). Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochemical Pharmacology, 33, 3269–3275.PubMed
104.
Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., et al. (1991). ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Research, 51, 5579–5586.PubMed
105.
Taylor, G. A., Jackman, A. L., Calvert, A. H., & Harrap, K. R. (1984). Plasma nucleoside and base levels following treatment with the new thymidylate synthetase inhibitor CB 3717. Advances in Experimental Medicine and Biology, 165 Pt B, 379–382.PubMed
106.
Perumal, M., Pillai, R. G., Barthel, H., Leyton, J., Latigo, J. R., Forster, M., et al. (2006). Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Research, 66, 8558–8564.PubMed
107.
Hu, Y. C., Komorowski, R. A., Graewin, S., Hostetter, G., Kallioniemi, O. P., Pitt, H. A., et al. (2003). Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clinical Cancer Research, 9, 4165–4171.PubMed
108.
Van Triest, B., & Peters, G. J. (1999). Thymidylate synthase: A target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology, 57, 179–194.PubMed
109.
Aschele, C., Lonardi, S., & Monfardini, S. (2002). Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treatment Reviews, 28, 27–47.PubMed
110.
Kissel, J., Brix, G., Bellemann, M. E., Strauss, L. G., Dimitrakopoulou-Strauss, A., Port, R., et al. (1997). Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Research, 57, 3415–3423.PubMed
111.
Klecker, R. W., Katki, A. G., & Collins, J. M. (1994). Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2′-fluoro-2′-deoxy-beta-d-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells. Molecular Pharmacology, 46, 1204–1209.PubMed
112.
Wang, H., Oliver, P., Nan, L., Wang, S., Wang, Z., Rhie, J. K., et al. (2002). Radiolabeled 2′-fluorodeoxyuracil-beta-d-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-d-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemotherapy and Pharmacology, 49, 419–424.PubMed
113.
Sun, H., Collins, J. M., Mangner, T. J., Muzik, O., & Shields, A. F. (2006). Imaging the pharmacokinetics of [18F-]FAU in patients with tumors: PET studies. Cancer Chemotherapy and Pharmacology, 57, 343–348.PubMed
114.
Sun, H., Collins, J. M., Mangner, T. J., Muzik, O., & Shields, A. F. (2003). Imaging [18F]FAU [1-(2′-deoxy-2′-fluoro-beta-d-arabinofuranosyl) uracil] in dogs. Nuclear Medicine and Biology, 30, 25–30.PubMed
115.
Eiseman, J. L., Brown-Proctor, C., Kinahan, P. E., Collins, J. M., Anderson, L. W., Joseph, E., et al. (2004). Distribution of 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: Rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. Clinical Cancer Research, 10, 6669–6676.PubMed
116.
Grierson, J. R., Brockenbrough, J. S., Rasey, J. S., Wiens, L. W., Schwartz, J. L., Jordan, R., et al. (2007). Evaluation of 5′-deoxy-5′-[18F-]fluorothymidine as a tracer of intracellular thymidine phosphorylase activity. Nuclear Medicine and Biology, 34, 471–478.PubMed
117.
Fei, X., Wang, J. Q., Miller, K. D., Sledge, G. W., Hutchins, G. D., & Zheng, Q. H. (2004). Synthesis of [18F-]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nuclear Medicine and Biology, 31, 1033–1041.PubMed
118.
Edler, D., Glimelius, B., Hallstrom, M., Jakobsen, A., Johnston, P. G., Magnusson, I., et al. (2002). Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. Journal of Clinical Oncology, 20, 1721–1728.PubMed
119.
Liang, Y., Diehn, M., Watson, N., Bollen, A. W., Aldape, K. D., Nicholas, M. K., et al. (2005). Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America, 102, 5814–5819.PubMed
120.
Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 98, 10869–10874.PubMed
121.
Lau, S. K., Boutros, P. C., Pintilie, M., Blackhall, F. H., Zhu, C. Q., Strumpf, D., et al. (2007). Three-gene prognostic classifier for early-stage non small-cell lung cancer. Journal of Clinical Oncology, 25, 5562–5569.PubMed
122.
Lu, Y., Lemon, W., Liu, P. Y., Yi, Y., Morrison, C., Yang, P., et al. (2006). A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Medicine, 3, e467.PubMed
123.
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., et al. (2004). Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proceedings of the National Academy of Sciences of the United States of America, 101, 9309–9314.PubMed
124.
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., et al. (1999). Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proceedings of the National Academy of Sciences of the United States of America, 96, 9212–9217.PubMed
125.
Whitfield, M. L., Sherlock, G., Saldanha, A. J., Murray, J. I., Ball, C. A., Alexander, K. E., et al. (2002). Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Molecular Biology of the Cell, 13, 1977–2000.PubMed
Metadata
Title
The role of DNA synthesis imaging in cancer in the era of targeted therapeutics
Authors
Sridhar Nimmagadda
Anthony F. Shields
Publication date
01-12-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9148-5

Other articles of this Issue 4/2008

Cancer and Metastasis Reviews 4/2008 Go to the issue

NON-THEMATIC REVIEW

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents

OriginalPaper

Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children

OriginalPaper

Imaging of integrin αvβ3 expression

NON-THEMATIC REVIEW

Cell cycle control and adhesion signaling pathways in the development of metastatic melanoma

OriginalPaper

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

OriginalPaper

Imaging matrix metalloproteinases in cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits